Treace Medical Concepts (TMCI) Receivables (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Receivables for 7 consecutive years, with $28.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 5.28% year-over-year to $28.7 million; the trailing twelve-month figure through Jun 2026 stood at $28.7 million (down 5.28% YoY), and the FY2025 full-year result was $42.2 million, up 3.31% from the prior year.
• Receivables slipped to $28.7 million in Q2 2026 per TMCI's latest filing, from $30.4 million in the prior quarter.
• Across five years, Receivables topped out at $42.2 million in Q4 2025 and bottomed at $16.0 million in Q1 2022.
• Historically, Receivables has averaged $28.5 million across 5 years, with a median of $29.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Receivables soared 65.03% in 2023, then retreated 6.14% in 2024.
• Over 5 years, Receivables stood at $29.2 million in 2022, then jumped by 30.5% to $38.1 million in 2023, then increased by 7.09% to $40.8 million in 2024, then increased by 3.31% to $42.2 million in 2025, then slumped by 31.84% to $28.7 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $28.7 million, $30.4 million, and $42.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.